OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by Wall Street Zen

Key Points

• OKYO Pharma has been upgraded to a "hold" rating by Wall Street Zen in a recent report.
• HC Wainwright has reiterated a "buy" rating on OKYO Pharma, setting a price target of $7.00.
• The company is focused on developing therapeutics for inflammatory eye diseases and its lead product candidate, OK-101, is currently in Phase II clinical trials.

Wall Street Zen upgraded shares of OKYO Pharma (NASDAQ:OKYO - Free Report) to a hold rating in a research report report published on Saturday.

Separately, HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of OKYO Pharma in a report on Monday, May 5th.

OKYO Pharma Stock Down 4.1%

OKYO stock traded down $0.13 during mid-day trading on Friday, hitting $2.99. The company had a trading volume of 60,209 shares, compared to its average volume of 171,186. OKYO Pharma has a 12-month low of $0.85 and a 12-month high of $3.35. The company has a 50-day moving average price of $2.64 and a 200 day moving average price of $1.78.

Hedge Funds Weigh In On OKYO Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC bought a new position in OKYO Pharma in the 2nd quarter worth about $28,000. Dauntless Investment Group LLC bought a new position in shares of OKYO Pharma during the first quarter valued at approximately $2,526,000. Finally, FNY Investment Advisers LLC bought a new position in shares of OKYO Pharma during the first quarter valued at approximately $25,000. 2.97% of the stock is currently owned by institutional investors.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.